We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » KALI LABORATORIES PURCHASE BOOSTS PAR'S R&D CAPABILITIES
KALI LABORATORIES PURCHASE BOOSTS PAR'S R&D CAPABILITIES
April 20, 2004
The parent company of generic firm Par Pharmaceuticals on April 13 said it would acquire generic firm Kali Laboratories for $135 million — a move that more than doubles Par’s research and development capabilities.